Comparative Pharmacology
Head-to-head clinical analysis: MEPERGAN versus ULTRAM ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPERGAN versus ULTRAM ER.
MEPERGAN vs ULTRAM ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia. Promethazine is a phenothiazine antipsychotic that antagonizes histamine H1, dopamine D2, muscarinic acetylcholine, and alpha-adrenergic receptors, providing sedation and antiemetic effects.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits serotonin and norepinephrine reuptake.
Meperidine 50-100 mg and promethazine 25-50 mg IM/IV every 3-4 hours as needed. Maximum meperidine dose: 600 mg/day.
100 mg orally once daily initially, titrate up to 100 mg twice daily as needed; maximum 200 mg/day.
None Documented
None Documented
Meperidine: 3-4 hours (terminal; increased in hepatic impairment). Promethazine: 9-16 hours (terminal; prolonged in elderly).
The terminal elimination half-life of tramadol is approximately 6.3 hours (range 5-9 hours), while its active metabolite M1 has a half-life of about 7.4 hours. Clinically, this supports dosing every 24 hours for the extended-release formulation.
Renal elimination of metabolites (meperidine: ~90% as metabolites, <5% unchanged; promethazine: ~70-80% as metabolites, <1% unchanged). Biliary/fecal excretion is minimal (<10% for both).
Renal excretion of tramadol and its metabolites accounts for approximately 90% of total elimination. About 10% is excreted unchanged, 30% as O-desmethyltramadol (M1), and the remainder as other minor metabolites. Biliary/fecal excretion is minimal (<10%).
Category C
Category C
Opioid Analgesic/Antiemetic Combination
Opioid Analgesic